MONEY

Akeso's Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 16, 2024 - 16:00
Akeso's Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024
Read More

Tags:

Previous Article

More rivers spill banks in central European floods, death toll rises

Next Article

Jefferies sees Generali stock undervalued amid improved risk profile and profits

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Hezbollah targets Israeli troops on Lebanese border, sirens in Beirut

Hezbollah targets Israeli troops on Lebanese border, si...

Tomas Kauer - Mode... Oct 9, 2024

Sierra Bancorp director sells $81,885 in stock

Sierra Bancorp director sells $81,885 in stock

Tomas Kauer - Mode... Nov 13, 2024

Riot Platforms director Hannah Cho sells $126k in stock

Riot Platforms director Hannah Cho sells $126k in stock

Tomas Kauer - Mode... Nov 21, 2024